Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR211: a peripheral CB1 receptor antagonist”（2018/12/17）
Title: NHRI technology, “DBPR211: a peripheral CB1 receptor antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: Cannabinoid receptor 1 (CB1) is expressed in several peripheral tissues related to metabolic control and its dysregulation contributes to metabolic disorders. DBPR211 is a highly selective antagonist of peripheral CB1 receptors. It exhibits beneficial …
